Abstract | INTRODUCTION: AIMS: The increase in the number of drugs available for the treatment of ADHD makes it possible to treat and cover a very wide range of different clinical situations. The purpose of this review is to perform an analysis of the literature on the two drugs. DEVELOPMENT: The study determines the strong points of both treatments, with special attention given to their mechanism of action, their tolerability and their efficacy. CONCLUSIONS: Extended-release guanfacine enables the professional to treat situations that are poorly covered by stimulants, such as children with irritability and tics, with a significant profile characterised by moderate efficacy and good tolerability and safety. The appearance of lisdexamphetamine has brought about a very important change because, according to the literature, it is a drug that, from the clinical point of view, is both complete and effective in improving the symptoms of ADHD. Moreover, it has a good safety profile.
|
Authors | D Martin Fernandez-Mayoralas, A L Fernandez-Perrone, N Munoz-Jareno, A Fernandez-Jaen |
Journal | Revista de neurologia
(Rev Neurol)
Vol. 64
Issue s02
Pg. S1-S8
(Mar 13 2017)
ISSN: 1576-6578 [Electronic] Spain |
Vernacular Title | Actualizacion en el tratamiento farmacologico del trastorno por deficit de atencion/hiperactividad: lisdexanfetamina y guanfacina de liberacion retardada. |
PMID | 28272733
(Publication Type: Journal Article, Review)
|
Chemical References |
- Adrenergic alpha-2 Receptor Agonists
- Central Nervous System Stimulants
- Delayed-Action Preparations
- Guanfacine
- Lisdexamfetamine Dimesylate
|
Topics |
- Adrenergic alpha-2 Receptor Agonists
(therapeutic use)
- Attention Deficit Disorder with Hyperactivity
(drug therapy)
- Central Nervous System Stimulants
(therapeutic use)
- Delayed-Action Preparations
- Guanfacine
(therapeutic use)
- Humans
- Lisdexamfetamine Dimesylate
(therapeutic use)
|